Like the Oxford/AstraZeneca jab, the Valneva vaccine conform with the standard cold chain requirements, which is between 2C and 8C.
The Valneva candidate vaccine is being tested on 150 volunteers at testing sites in Birmingham, Bristol, Newcastle and Southampton.
These tests will show whether the vaccine produces a safe and effective immune response against Covid-19.
If successful, larger tests will be planned for April 2021, with more than 4,000 UK volunteers taking two doses.
These trials will include those aged 18-65 as well as over-65s.
What’s happening with the Johnson & Johnson vaccine?
Johnson & Johnson, which owns the pharmaceutical firm Janssen, announced on Jan 29 that its single-dose vaccine was effective in preventing COVID-19.
Clinical data from phase 3 trials show the vaccine is 66 per cent effective at preventing moderate to severe Covid-19 but offers high protection against people needing to go to hospital.
In the trial of nearly 44,000 volunteers, the level of protection against moderate and severe COVID-19 was 66 per cent in Latin America and 57 per cent in South Africa, where a particularly worrying variant of the novel coronavirus is circulating.
However, J & J said the jab was 85 per cent effective in preventing severe disease “and demonstrated complete protection against Covid-19 related hospitalisation and death as of day 28”.
Those results compare to the high bar set by the Pfizer Inc/BioNTech SE and Moderna vaccines, which were around 95 per cent effective in preventing Covid-19. However, those trials were conducted mainly in the United States and before the spread of new more infectious variants.
Unlike the Pfizer/BioNTech and Moderna vaccines, J&J’s does not require a second shot weeks after the first or need to be kept frozen, making it a strong candidate for use in parts of the world with weak transportation infrastructure and insufficient cold storage facilities.
The vaccine uses a common cold virus known as adenovirus type 26 to introduce coronavirus proteins into cells in the body and trigger an immune response.
The UK has already pre-ordered 30 million doses of this vaccine but has the option to reserve a further 22 million, which will assist the Government in its aim to vaccinate the four most vulnerable groups of citizens by mid-February.